Sanofi downsizing in France drags on
Government report to help decide fate of R&D center in Toulouse.
Sanofi CEO Chris Viehbacher has been openly critical of his research operation in Toulouse, France. He said the researchers are costing too much money and haven’t developed an important drug in 20 years. The company is building its main development brain trust in Boston around its Genzyme biotech operation. Despite all of that, he can’t seem to rid himself of the
By month’s end Sanofi ($SNY) expects to get the results of a
French labor laws and the French resistance, so to speak, will make closing Toulouse extremely difficult, as Sanofi execs found out last fall when it first floated that idea. While drugmakers lay off workers by the thousands in the U.S. and elsewhere, closing a
French pride is at stake in the fight over the Toulouse site because the jobs there represent the kind of highly paid,
While the future of the Toulouse facility remains up in the air, Sanofi is still negotiating with the 900 workers it does plan to let go in the restructuring, The Wall Street Journal reported. Last month, a court ruled that Sanofi violated labor laws by not spelling out to unions exactly how many jobs and which ones were to be eliminated, delaying the process again.